Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Aztreonam
Drug ID BADD_D00206
Description A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
Indications and Usage For the treatment of the following infections caused by susceptible gram-negative microorganisms: urinary tract infections, lower respiratory tract infections, septicemia, skin and skin-structure infections, intra-abdominal infections, and gynecologic infections.
Marketing Status approved
ATC Code J01DF01
DrugBank ID DB00355
KEGG ID D00240
MeSH ID D001398
PubChem ID 2274
TTD Drug ID D0F2XV
NDC Product Code 24525-0025; 13538-001; 0409-0830; 54087-160; 63323-401; 63323-402; 52952-001; 0003-2570; 0003-2560; 73301-008; 13538-008; 61958-0901; 0409-0829; 13538-009
UNII G2B4VE5GH8
Synonyms Aztreonam | Az-threonam | Az threonam | Azthreonam | SQ-26,776 | SQ 26,776 | SQ26,776 | Urobactam | Azactam
Chemical Information
Molecular Formula C13H17N5O8S2
CAS Registry Number 78110-38-0
SMILES CC1C(C(=O)N1S(=O)(=O)O)NC(=O)C(=NOC(C)(C)C(=O)O)C2=CSC(=N2)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Activated partial thromboplastin time prolonged13.01.02.001--
Agranulocytosis01.02.03.0010.000049%-
Alanine aminotransferase increased13.03.04.005--
Anaemia01.03.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.0060.000049%
Anaphylactic shock10.01.07.002; 24.06.02.004---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.0010.000073%-
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.001---
Blood creatine increased13.13.01.001---
Blood creatinine increased13.13.01.004--
Body temperature increased13.15.01.001---
Breast tenderness21.05.05.004---
Breath odour07.01.06.002---
Bronchospasm10.01.03.012; 22.03.01.004--
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.0020.000049%-
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Cholestasis09.01.01.0010.000097%-
Clostridium difficile colitis07.19.01.004; 11.02.02.004---
Condition aggravated08.01.03.0040.000049%-
Confusional state17.02.03.005; 19.13.01.0010.000049%
Cough22.02.03.001--
Death08.04.01.0010.000316%
Dermatitis23.03.04.002---
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diarrhoea07.02.01.001--
Diplopia06.02.06.002; 17.17.01.005---
Discomfort08.01.08.003---
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages